Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR009119)
Formula
SVG example
Unclear
Reactant GS-441524-MP Product GS-441524-DP
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009118 GS-441524 GS-441524-MP Unclear - Unclear GS-441524 [1]
MR014047 Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Remdesivir Nucleoside Monophosphate Unclear Remdesivir [2]
MR013219 Remdesivir M1 Remdesivir Nucleoside Monophosphate Unclear Remdesivir [2]
MR013212 Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Remdesivir Nucleoside Monophosphate Oxidation - Deamination Remdesivir [3]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR014046 Remdesivir Nucleoside Monophosphate GS-441524 Unclear Remdesivir [4]
MR014048 Remdesivir Nucleoside Monophosphate Remdesivir Nucleoside Triphosphate Conjugation - Phosphorylation Remdesivir [5]
MR013214 Remdesivir Nucleoside Monophosphate GS-441524 Unclear Remdesivir [3]
MR013213 Remdesivir Nucleoside Monophosphate Remdesivir Nucleoside Triphosphate Conjugation - Phosphorylation Remdesivir [3]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009120 GS-441524-DP GS-443902 Unclear - Unclear GS-441524 [1]
References
1 Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
2 Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
3 Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
4 Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction
5 Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.